Drug intelligence / Profile preview

Chang-An Jun-Tai Granule (c453ee)

Development stage: Preclinical
Lead developer: First Affiliated Hospital of Guangzhou University of Chinese Medicine
Administration: Oral

Overview

**Chang-An Jun-Tai Granule** is an oral traditional Chinese medicine granular formulation being clinically evaluated in China for **irritable bowel syndrome with diarrhea**. A multicenter, randomized, placebo-controlled trial sponsored by The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine was registered as ChiCTR1900026373. The product is a traditional Chinese medicine formula; its individual constituents, defined molecular targets, and validated pharmacologic mechanism have not been publicly established in the identified registry record.

Other names: Chang-An Jun-Tai GranuleChang-An-Jun-Tai Granules肠安菌泰颗粒

Beyond the preview

Go deeper on Chang-An Jun-Tai Granule (c453ee).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chang-An Jun-Tai Granule (c453ee).

Explore the full profile